Intravenous Vitamin C (IVC)

Intravenous Vitamin C (IVC) in Cancer Therapy: A Potent Alternative

High-dose vitamin C is an antioxidant that holds potential in protecting cells from free radical damage and enhancing the body's immune system. This, in turn, increases its capacity to combat cancer. Laboratory studies have demonstrated its ability to reduce cell proliferation in various cancers, improve patients' quality of life, and mitigate cancer-related side effects. In high doses, vitamin C can directly damage cancer cells' DNA and energy centers.

Cancer is a complex disease, with chemotherapy being the primary treatment in conventional oncology. However, alternative treatments, such as high-dose intravenous vitamin C (IVC), are available for patients who prefer not to undergo conventional therapy. The Dove Clinic in Winchester, Hampshire, extensively utilizes high-dose IVC. Dr. Julian Kenyon of the Dove Clinic considers high-dose IVC to be among their most effective cancer treatments.

Vitamin C, a water-soluble antioxidant, has several biological functions, including maintaining proper immune cell function. Although it typically acts as an antioxidant, it can also function as a pro-oxidant, similar to chemotherapy. Vitamin C converts free radicals into hydrogen peroxide, a molecule capable of damaging cell membranes. Tumor cells possess 10 to 100 times less catalase, an enzyme that neutralizes hydrogen peroxide, than normal cells, rendering them more susceptible to hydrogen peroxide. Vitamin C accumulates in solid tumors at concentrations higher than those in the surrounding normal tissue.

To achieve the efficacy of high-dose IVC, plasma vitamin C levels between 300-400 milligrams per 100cc are required, which can only be attained via intravenous infusion. Infusions of 75 grams of vitamin C daily for three weeks are necessary to reach these plasma levels. The highest plasma vitamin C level achievable through oral supplementation is 4.5 milligrams per 100cc.

Recent research from the University of Iowa has shown that high-dose IVC, delivered through intravenous infusions, can slow the rate of cancer growth either on its own or in conjunction with chemotherapy and radiotherapy. Additionally, it can reduce the side effects of conventional medicine and has no known side effects from IVC itself. This research disproves the theory that vitamin C provides tumors with antioxidant protection from chemotherapy.

A 2008 study by Qi Chen and his colleagues in PubMed examined pro-oxidant levels of intravenous vitamin C in animals with brain tumors and concluded that the only way to achieve the required hydrogen peroxide cytotoxicity levels was to administer pharmacological levels intravenously. Other research supports the use of vitamin C megadoses in cancer therapy, including work by Dr. Fukumi Morishiga, who used vitamin C with an extract of Reishi mushrooms and demonstrated regression or disappearance of various types of cancers, from breast to brain cancer.

Benefits of IV Vitamin C for Cancer Patients:

1. IV Vitamin C is a potent antioxidant that effectively combats free radicals and eliminates them from the body, preventing the formation of new cancerous cells and inhibiting the growth of existing tumors.
2. Vitamin C enhances the immune system, which is vital in fighting cancer.
3. Vitamin C also improves the quality of life of cancer patients, increasing their well-being, energy levels, appetite, and resilience to the adverse effects of other treatments.

Furthermore, high doses of IV Vitamin C have been shown to be selectively cytotoxic to cancer cells with mutations in KRAS or BRAF oncogenes, which are present in over half of colorectal tumors and are resistant to treatment.

The Evidence for IV Vitamin C in Cancer Treatment:

The science on IV Vitamin C in cancer treatment is not new, with Linus Pauling and Ewan Cameron publishing their landmark study on IV Vitamin C in cancer over 40 years ago. In this study, they found that IV Vitamin C increased the survival time of patients with advanced cancer who received a low dose of IV Vitamin C compared to those who did not. Despite this long history of research, the use of IV Vitamin C in cancer treatment continues to be studied at numerous sites worldwide.

Conclusion:

In conclusion, the evidence supporting the use of IV Vitamin C in cancer treatment continues to grow, with many hospitals and clinics around the world using it as a safe, effective, and affordable element in cancer treatment. It is our opinion that the evidence for the IV use of Vitamin C in cancer is so strong that it should be considered a mainstay in any and all treatment plans for cancer patients.

By integrating high-dose intravenous Vitamin C therapy into cancer treatment plans, patients may benefit from the potent antioxidant properties, immune system enhancement, and improved quality of life. As research continues to develop, it is crucial to remain informed about the evolving evidence supporting IVC in cancer treatment, as it may become an increasingly essential component in the battle against cancer.

• The use of intravenous Vitamin C in cancer treatment has been a topic of debate for decades, with conflicting results from clinical trials.

• IV Vitamin C is a potent antioxidant that effectively fights free radicals and eliminates them from the body, preventing the formation of new cancerous cells and inhibiting the growth of existing tumors.

• IV Vitamin C enhances the immune system and improves the quality of life of cancer patients.

• High doses of IV Vitamin C have been shown to be selectively cytotoxic to cancer cells, destroying cancer cells with mutations in KRAS or BRAF oncogenes.

• The evidence for the use of IV Vitamin C in cancer treatment continues to grow, with many hospitals and clinics around the world using it as a safe, effective, and affordable element in cancer treatment.

• It is our opinion that the evidence for the IV use of Vitamin C in cancer is so strong that it should be considered a mainstay in any and all treatment plans for cancer patients.

References:

1. https://www.cancer.gov/research/key-initiatives/ras/ras-central/blog/2020/yun-cantley-vitamin-c

2. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6115501/

3. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5927785/

4. http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4388666/

5. https://sciencebasedmedicine.org/high-dose-vitamin-c-and-cancer-has-linus-pauling-been-vindicated/

6. https://www.cancertreatmentsresearch.com/high-dose-vitamin-c-cancer/

7. https://www.cancer.gov/research/key-initiatives/ras/ras-central/blog/2020/yun-cantley-vitamin-c

8. http://annonc.oxfordjournals.org/content/19/11/1969.full

9. https://www.ncbi.nlm.nih.gov/pubmed/26256994

10. https://www.ncbi.nlm.nih.gov/pubmed/1787807

11. https://www.cancertreatmentsresearch.com/?p=1489

12. http://www.nature.com/news/vitamin-c-injections-ease-ovarian-cancer-treatments-1.14673

13. http://meyercancer.weill.cornell.edu/news/2015-11-05/vitamin-c-kills-colorectal-cancer

14. https://www.nature.com/articles/s41568-019-0135-7

15. Horgan, J (1993). "Profile: Linus C. Pauling – Stubbornly Ahead of His Time". Scientific American. 266 (3): 36–40. Bibcode:1993SciAm.266c..36H. doi:10.1038/scientificamerican0393-36

16. Carr AC, Maggini S. Vitamin C and Immune Function. Nutrients. 2017 Nov 3;9(11). pii: E1211. doi: 10.3390/nu9111211.

17. Cameron E, Pauling L. Supplemental ascorbate in the supportive treatment of cancer: Prolongation of survival times in terminal human cancer. Proc Natl Acad Sci U S A. 1976;73(10):3685-3689. (PubMed)

18. Gloria Bonuccelli, Ernestina Marianna De Francesco, Rianne de Boer, Herbert B. Tanowitz, and Michael P. Lisanti "NADH autofluorescence, a new metabolic biomarker for cancer stem cells: Identification of Vitamin C and CAPE as natural products targeting "stemness." Oncotarget. 2017 Mar 28; 8(13): 20667–20678. Published online 2017 Feb 16. doi: 10.18632/oncotarget.15400 PMCID: PMC5400535 PMID: 28223550

19. Yun, J., Mullarky, E., Lu, C., Bosch, K.N., Kavalier, A., Rivera, K., Roper, J., Chio, I., Giannopoulou, E.G., Rago, C., Muley, A., Asara, J.M., Paik, J., Elemento, O., Chen, Z., Pappin, D.J., Dow, L.E., Papadopoulos, N., Gross, S.S. & Cantley, L.C. “Vitamin C selectively kills KRAS and BRAF mutant colorectal cancer cells by targeting GAPDH”. Science 350, 1391-1396. (2015)

20. NCI Review of IVC - University of Iowa research - University of Iowa clinical studies on IVC with brain cancer and lung cancer.